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Abstract
Background: Dietary supplement use among recreational athletes is common, with the intention of reducing
inflammation and improving recovery. We aimed to describe the relationship between omega-3 fatty acid
supplement use and inflammation induced by strenuous exercise.
Methods: C-reactive protein (CRP) concentrations were measured in 1002 healthy recreational athletes before and
24 h after a 91-km bicycle race. The use of omega-3 fatty acid supplements was reported in 856 out of 1002
recreational athletes, and the association between supplement use and the exercise-induced CRP response was
assessed.
Results: Two hundred seventy-four subjects reported regular use of omega-3 fatty acid supplements. One hundred
seventy-three of these used cod liver oil (CLO). Regular users of omega-3 fatty acid supplements had significantly
lower basal and exercise-induced CRP levels as compared to non-users (n = 348, p < 0.001). Compared to non-users,
regular users had a 27% (95% confidence interval (CI): 14–40) reduction in Ln CRP response (unadjusted model, p <
0.001) and 16% (95% CI: 5–28, p = 0.006) reduction after adjusting for age, sex, race duration, body mass index, delta
creatine kinase, MET hours per week, resting heart rate and higher education. CLO was the primary driver of this
response with a 34% (95% CI: 19–49) reduction (unadjusted model, p < 0.001) compared to non-users.
Corresponding numbers in the adjusted model were 24% (95% CI: 11–38, p < 0.001).
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Conclusion: Basal CRP levels were reduced, and the exercise-induced CRP response was attenuated in healthy
recreational cyclists who used omega-3 fatty acid supplements regularly. This effect was only present in regular
users of CLO.
Trial registration: NCT02166216, registered June 18, 2014 – Retrospectively registered.
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Background
Prolonged strenuous physical exercise induces inflamma-
tion [1, 2]. An increased exercise-induced inflammation is
associated with attenuated recovery and exercise-induced
muscular damage and soreness [3]. The use of omega-3
fatty acid supplements has been associated with a reduc-
tion in inflammatory markers in both recreational and
elite athletes in several small-scale randomized trials [4].
However, some studies have reported no effect of omega-
3 fatty acid supplements on inflammatory markers follow-
ing exercise [5, 6]. These diverging findings may relate to
type, intensity and duration of exercise, the population
studied, timing of sampling and the type of inflammatory
markers used to assess the response [7].
Omega-3 fatty acid supplements attenuate inflamma-
tion by modulating cell membrane function, down-
regulating pro-inflammatory cytokines (such as IL-6), re-
ducing production of arachidonic acid derivatives and
reactive oxygen species [8]. Omega-3 fatty acid supple-
ments contain a variety of eicosapentaenoic acids (EPA,
20:5n-3) and docosahexaenoic acids (DHA, 22:6n-3),
and these substances have different effects on the in-
flammatory response. EPA is a precursor of leukotriens,
attenuating cyclooxygenase 2 and arachidonic metabol-
ism, while DHA is the precursor for protectins [8].
These differences might be of importance when evaluat-
ing the effect of omega-3 fatty acid supplements. In
Norway, a supplement made from fresh arctic cod liver
oil (CLO, “Tran”) has traditionally been a popular
omega-3 fatty acid supplement. There is limited data on
the relationship between the use of omega-3 fatty acid
supplements and inflammation in recreational athletes,
and particularly on the use of CLO.
The primary aim of this study was to determine the rela-
tionship between regular consumption of omega-3 fatty acid
supplements and the exercise-induced inflammatory re-
sponse in a large population of healthy recreational athletes.
The secondary aim was to determine if there is a difference
in the inflammatory response comparing CLO (“Tran”) and
other types of omega-3 fatty acid supplements. C-reactive
protein (CRP) was used to assess the inflammatory response,
as CRP is a robust down-stream inflammatory marker of cy-
tokines such as IL-6 [9]. All data was acquired during the
same event, from a limited geographical territory to ensure
as homogeneous population as possible.
Methods
The North Sea Race Endurance Exercise Study (NEED
ED) is a prospective, observational study that sampled
data from 1002 presumably healthy recreational athletes
in conjunction with a 91 km mountain bike race (The
North Sea Race) in 2014. The study population consisted
of individuals who were physically active but who did
not train for competition at the same level of intensity
and focus as competitive athletes. As the focus of most
of the included subjects were to be physically fit and to
have fun, our study population were defined as recre-
ational athletes, consistent with the definition previously
used by Laquale [10]. A detailed description of exclusion
and inclusion criteria has been published previously [11].
The study subjects were asked about their habitual in-
take of omega-3 fatty acid supplements, including CLO
supplements. C-reactive protein levels were assessed be-
fore and 24 h following the race. The study was ap-
proved by the Regional Ethics Committee (REK 2013/
550) and complies with the Declaration of Helsinki. All
participants signed informed consent forms prior to
enrollment.
Supplement use
Data concerning supplement use was obtained by elec-
tronic questionnaire. Supplement use was reported as ei-
ther 1) no use, 2) sporadic use, 3) used only the last
couple of weeks, 4) used only in conjunction with the
race and 5) uses regularly. For data analysis, categories
2–4 were combined, and analyzed as sporadic use, as
only a few participants reported use in category 3 and 4.
No data regarding manufacturer or dosage of supple-
ments were collected. “Regular users” was the main
comparator. Contents of examples of different supple-
ments are outlined in Table 1.
Data collection
Data was collected on site the day before the race, and
at 3- and 24 h following the race. Only minimal increase
in CRP was observed at 3 h post-race (Supplementary
Figure 1), and therefore data on CRP increase and its re-
lation to supplement use was analyzed for the CRP in-
crease between baseline and 24 h post-race. Data
collection included blood pressure, electrocardiogram,
waist circumference, body weight and blood samples.
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Also, online surveys were used to assess demographics,
cardiovascular risk factors, training loads and training
experience. Use of different kinds of supplements were
also included in the online survey.
Blood samples
Venous blood samples were drawn from the antecubital
vein. Serum samples were centrifuged within 60 min at
2000 G for 10 min and analyzed within 24 h at Stavanger
University Hospital. CRP was analyzed on Architect
c16000TM (Abbott Diagnostics, Abbot park, Illinois,
USA), using quantitative immunoturbometric determin-
ation of CRP (Multigen CRP Vario assay). Creatin kinase
(CK), creatinine, low-density lipoprotein (LDL) and
high-density lipoprotein (HDL) were also analyzed on
Architect c1600TM (Abbott Diagnostics, Abbot park,
Illinois, USA). Plasma b-type natriuretic peptide (BNP)
was analyzed on Architect SR2000i (Abbott Diagnostics).
Glomerular filtration was estimated (eGFR) using the
CKD-EPI equation. Haemoglobin was measured using
Sysmex XE-5000 (Sysmex, Kobe, Japan). These variables
were included in the baseline assessment of the included
subjects.
Statistical analysis
Normally distributed continuous variables are reported
as mean ± SD. Continuous variables with a markedly
skewed distribution are reported as median (25th–75th
percentile). The Shapiro-Wilk test was used to test for
normality. A two-tailed p-value of < 0.05 was considered
significant. Between group differences was assessed by
Mann-Whitney U test or Kruskall-Wallis test, as appro-
priate. Multiple linear regression analysis was performed
using an enter model that compared regular users of
omega-3 fatty acid supplements to those who reported
non- or sporadic use. Data in the multiple regression
models are presented as B (95% confidence interval). Ln-
transformation of the dependent variable (CRP) was per-
formed due to skewed residuals. Adjustments were con-
ducted based on bivariate correlations (Supplementary
Table 1). Variables with marked collinearity were ex-
cluded. The following variables were assessed in bivari-
ate correlation analysis with the CRP response: Age,
body mass index (BMI), body weight, waist circumfer-
ence, systolic blood pressure (SBP), diastolic blood pres-
sure (DBP), eGFR, Framingham risk score, resting heart
rate, MET hours per week, number of competitions/5
years, race duration and delta CK (baseline-24 h). Body
mass index was chosen to represent body composition,
and due to collinearity body weight and waist circumfer-
ence were excluded. Similarly, number of competition/5
years was omitted due to collinearity with race duration.
Age and sex were included into the multiple regression
models due to the known impact of these variables on
the body’s physiological responses. Delta CK was in-
cluded due to the known association between muscle-
derived interleukin 6 and CRP, and higher education
was included to adjust for socioeconomic status. Sensi-
tivity analysis are included in the supplementary appen-
dix with multiple linear regression analysis that
compares regular users of CLO to subjects who reported
no use of either supplements (n = 612). Statistical ana-
lysis were performed using the statistical software pro-
gram SPSS version 24.
Results
Study subjects were 46.8 (40.1–52.6) years old and 783
(79.1%) were males. They finished the 91 km mountain
bike race in 3.8 (3.4–4.3) hours. CRP increased from 0.7
(0.4–1.3) mg/L to 6.9 (4.0–11.8) mg/L, p < 0.001, 24 h
following the race.
Table 1 The contents and differences between different omega-3 fatty acid supplements and CLO from the market leaders in












PUFAs 1.25 g 0.202 g 0.650 g 0.70 g 1.20 g
-
DHA
0.43 g 0.096 g 0.22 g na 0.60 g
- EPA 0.60 g 0.080 g 0.33 g na 0.40 g
Vitamins
- A na na 250 μg 250 μg 250 μg
- D na na 20 μg 15 μg 10 μg
- E na na 10 mg 10mg 10mg
Na not available. PUFA polyunsaturated fatty acids
1 Contents of 2 capsules, recommended 1–4 capsules/day
2 Contents of 2 capsules, recommended 2–4 capsules/day
3 Contents of 2 capsules
4 Contents of 5 ml CLO. Møllers had 97% of 2017 marked share on CLO supplements, according to the manufacturer
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In total, 856 (85%) of the included subjects reported data
on the use of supplements containing omega-3 fatty acids
(Fig. 1). Supplements were used either regularly (n = 274),
occasionally (n = 234) or never (n = 348). Baseline charac-
teristics of the subjects are outlined in Table 2. Regular
users of omega-3 fatty acid supplements were older, had
lower BMI and body weight, and reported higher training
loads prior to the race than sporadic and non-users.
Omega-3 fatty acid supplement use, CRP and creatine
kinase concentrations
Subjects who reported regular use of omega-3 fatty acid
supplements were found to have lower CRP-levels both
before and following the race as compared to non-users
(p < 0.001) and to non-users and sporadic users (p <
0.001, Fig. 2). In multiple regression analysis, regular use
of any omega-3 fatty acid supplements was associated
with a 16% (95% confidence interval: − 28- -5%), p =
0.006 decrease in ln-transformed delta CRP level as
compared to subjects who reported no or sporadic use
of omega-3 fatty acid supplements (Table 3, Model 4).
There was a highly significant increase in creatine kin-
ase values following the race (p < 0.001), but no differ-
ence between the different categories of supplement
users (Supplementary Figure 2). There was a significant
bivariate correlation (r = 0.27, p < 0.001) between the
delta value of creatine kinase and CRP (baseline versus
24 h). In the multiple regression models, delta CK
remained an independent predictor of the CRP response,
but did not affect the overall results of lower CRP
among regular users of omega-3 fatty acid supplements.
Difference between omega-3 fatty acid supplements
Cod liver oil (CLO) was the most used omega-3 fatty
acid supplement (n = 173). Users of CLO were more
often male but had otherwise similar baseline character-
istics as regular users of other omega-3 fatty acid supple-
ments (Supplementary Table 2). When the CRP levels
were examined in subgroups of regular users of other
omega-3 fatty acid supplements (n = 120) or regular
users of CLO, only CLO users were found to have sig-
nificantly lower CRP levels as compared to non-users
and sporadic users (Fig. 2). This translated into a de-
crease in Ln-transformed CRP levels of 24% (CI: − 38-
-11) %, p < 0.001 following the race for regular users of
CLO in the fully adjusted multiple regression models
(Supplementary Table 3). Sensitivity analysis confirmed
that regular users of CLO supplements had lower CRP
response also in comparison to subjects who reported
no use (n = 348, subjects with sporadic use excluded,
Supplementary Table 4). Furthermore, a direct compari-
son within subjects who reported regular use of either
omega-3 supplements (n = 101) or CLO (n = 154) were
undertaken (regular users of both supplements ex-
cluded). This analysis showed a borderline significant
trend in lower CRP levels for the regular users of CLO
(Supplementary Table 5).
Regular use of both CLO and another omega-3 fatty
acid supplement was reported in 19 subjects (1.9%),
representing the group with the potentially highest in-
take of omega-3 polyunsaturated fatty acids (PUFAs).
CRP at baseline was 0.6 (0.4–1.1) mg/L increasing to 5.8
(3.2–11.0) mg/L at 24-h following the race. No add-
itional effect on the inflammatory response to exercise
was observed in this group as compared to those who
only reported regular use of CLO.
Race duration and body mass index were also inde-
pendent predictors of the CRP-response in the multiple
regression models. The largest differences in delta CRP
levels between regular users and non-regular users of
Fig. 1 Outline of study participants and use of omega-3 fatty acid supplements. 119 subjects used both cod liver oil and other omega-3 fatty
acid supplement. 238 subjects reported sporadic use of both cod liver oil and other omega-3 fatty acid supplement
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CLO were observed for those with the highest BMI (6.2
(3.4–10.8) vs 8.5 (5.6–15.3) mg/L, p = 0.003) and the lon-
gest race duration (5.4 (2.9–10.9) vs 9.2 (5.1–16.5) mg/L,
p < 0.001). However, the attenuation of the CRP re-
sponse for regular users of CLO were evident across ter-
tiles (Fig. 3).
Discussion
This is the first large-scale study to explore and compare
the effects of omega-3 fatty acid supplement use on CRP
levels following the induction of a sterile inflammatory
response by strenuous physical exercise in healthy indi-
viduals. There are several novel and important findings.
First, use of omega-3 fatty acid supplements was com-
mon in the present cohort, with about two-thirds of sub-
jects reporting either regular or sporadic use of these
supplements. Second, subjects who reported regular use
of omega-3 fatty acid supplements had lower baseline
and exercise-induced CRP levels compared with other
subjects. Third, in subgroup analysis only regular use of
CLO was associated with lower baseline- and exercise-
induced CRP levels. Fourth, in multiple regression
Table 2 Baseline characteristics of subjects who reported on use of omega-3 fatty acid supplements, and baseline characteristics of
the sub cohorts who reported regular or sporadic use of omega-3 fatty acid supplements and the subjects who reported no use
these supplements. P-value reflects between-group differences between regular users, sporadic users and no users. Data are







No use (n = 348) p-value
Age, years 46.8 (40.3–58.0) 49.2 (41.8–54.7) 45.8 (39.1–51.7) 45.7 (40.0–51.1) < 0.001
Males, n (%) 656 (76.6) 194 (70.8) 182 (77.8) 280 (80.5) 0.004
BMI, kg/m2 25.2 (23.7–27.4) 25.0 (23.2–26.8) 25.6 (23.8–27.9) 25.3 (24.0–27.6) 0.006
Body weight, kg 81.4 (74.2–89.1) 79.5 (71.8–87.4) 82.4 (74.3–90.5) 82.6 (75.4–89.3) 0.007
Waist circumference, cm 85.0 (80.0–92.0) 84.0 (79.3–90.9) 86.0 (79.0–93.0) 86.0 (81.0–93.5) 0.015
Systolic blood pressure, mmHg 136 (126–148) 136 (127–145) 136 (126–149) 137 (126–148) 0.67
Diastolic blood pressure, mmHg 79 (73–86) 79 (73–86) 80 (73–86) 80 (74–87) 0.58
Resting HR, beats/min 59 (53–67) 60 (54–67) 58 (52–67) 58 (53–65) 0.24
Current smokers, n (%) 11 (1.2) 3 (0.7) 1 (0.0) 7 (2.0) 0.28
Framingham risk score, %1 1.0 (0–5) 1 (0–5) 1 (0–4) 1 (0–4) 0.70
MET hours per week 2 51 (32–78) 54 (33–83) 47 (28–75) 51 (33–75) 0.009
Number of races past 5 y, n 7 (3–15) 7 (4–16) 5 (2–12) 7 (3–15) 0.072
Higher education, n (%) 532 (62.1) 166 (60.6) 158 (67.5) 208 (59.8) 0.16
Race performance
Race duration, h 3.7 (3.3–4.1) 3.8 (3.3–4.4) 3.7 (3.4–4.1) 3.6 (3.2–4.1) 0.23
Maximal HR during race, bpm 3 178 (170–186) 176 (169–185) 179 (171–185) 178 (172–187) 0.27
Maximal HR of estimated maximal HR, % 3 100.4 (96.7–104.5) 100.1 (95.9–104.8) 100.1 (96.3–103.6) 100.4 (97.4–105.1) 0.67
Mean HR during race, bpm 3 157 (148–165) 154.0 (145.0–163.0) 158.0 (150.0–165.0) 158.0 (149.0–165.0) 0.051
Mean HR of estimated maximal HR, % 3 88.5 (84.5–92.5) 88.3 (83.0–92.3) 88.2 (84.4–92.5) 89.0 (85.4–92.7) 0.33
Blood samples at baseline
BNP, pg/mL 13.4 (10.0–21.1) 14.3 (10.0–22.6) 14.0 (10.0–21.4) 12.5 (10.0–19.2) 0.06
CRP, mg/L 0.7 (0.4–1.3) 0.6 (0.3–1.1) 0.8 (0.5–1.3) 0.8 (0.4–1.5) 0.001
Creatinine, umol/L 83.7 ± 11.8 82.4 ± 12.5 84.3 ± 11.9 84.3 ± 11.1 0.051
eGFR, mL/min/1.73m2 91.2 ± 12.8 90.1 ± 13.0 91.4 ± 12.9 91.8 ± 12.5 0.33
LDL, mmol/L 3.2 (2.6–3.7) 3.1 (2.4–3.8) 3.2 (2.6–3.7) 3.2 (2.7–3.8) 0.20
HDL, mmol/L 1.5 (1.3–1.7) 1.5 (1.3–1.8) 1.5 (1.2–1.7) 1.4 (1.2–1.6) < 0.001
Haemoglobin, g/dL 14.5 ± 1.0 14.4 ± 1.0 14.4 ± 1.0 14.5 ± 1.0 0.04
1 Framingham risk score: 10-year risk of death or myocardial infarction
2 MET =Metabolic equivalents (3.5 ml O2/kg/min). Estimated by IPAQ-SF
3 Self-reported data, available for 540 subjects (54.5%)
BMI body mass index, HR heart rate, BNP B-type natriuretic peptide, CRP C-reactive protein, eGFR estimated glomerular filtration rate, LDL low-density lipoproteins,
HDL high-density lipoprotein
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models, the beneficial effects of regular CLO consump-
tion, was evident in all models explored. These findings
imply that omega-3 fatty acid supplements, and particu-
larly CLO, are associated with a reduction in both basal
and exercise-induced inflammation in recreational
athletes.
Use of supplements
The use of dietary supplements in the general popula-
tion is common. Bailey et al. found that 49% of the gen-
eral population in the US uses dietary supplements [12].
Among athletes, the use of dietary supplements seems to
be even higher, but exact estimates are difficult and
Fig. 2 CRP increase from baseline to 24 h after the race, comparing non- or sporadic use of omega-3 fatty acids to a) regular use of any omega-3
fatty acid supplement, b) regular use of CLO and c) regular use of a non-CLO omega-3 fatty acid supplement
Table 3 Association between regular use of any omega-3 fatty acid supplements (n = 274) and change in concentrations of Ln-
transformed CRP (B (95% confidence interval)) compared with non- or sporadic users (n = 582)
Model 1 Model 2 Model 3 Model 4
CRP baseline
Regular use of any omega-3 −25 (−27- -12), p < 0.001 −25 (−28- -13), p < 0.001 −18 (−30- -7), p = 0.002 −19 (−31- -7), p = 0.002
CRP 24 h post-race
Regular use of any omega-3 −25 (−37- -14), p < 0.001 −23 (−34- -11), p < 0.001 −16 (−26- -5), p = 0.004 −16 (−26- -5), p = 0.003
Delta CRP 0-24 h
Regular use of any omega-3 −27 (−40- -14), p < 0.001 −24 (− 27- -11), p < 0.001 −17 (− 28- -5), p = 0.006 −16 (− 28- -5), p = 0.006
Model 1: Unadjusted, Model 2: adjusted for age and sex, Model 3: As for Model 2, but also adjusted for body mass index and race duration, Model 4: As for Model
3, but also adjusted for delta creatine kinase (baseline-24 h post-race), MET hours per week, resting heart rate and higher education
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approximately 14% of athletes use omega-3 fatty acid
supplements [13]. In Norway, there is a long tradition of
CLO supplement use. The main manufacturer reports
yearly sales of about 2.5 million bottles of CLO in
Norway (population: 5.4 million) [14]. Three studies
reporting on the use of CLO in the 1990–2000 found
between 18 and 45% of their cohorts reported regular
use of CLO supplements [15–17]. To our knowledge,
there are no previous studies on the use of CLO in ath-
letic cohorts.
The CRP response in relation to regular use of omega-3
fatty acid supplement
In this present analysis, regular use of omega-3 fatty acid
supplements, and in particular regular use of CLO, was
associated with lower CRP levels both at baseline and
following exercise. The difference in CRP levels follow-
ing exercise was most pronounced in the least fit sub-
jects and in the subjects with the highest BMI levels
(Fig. 3).
The association between intake of omega-3 fatty acid
supplements and inflammation has been studied in sev-
eral cohorts, but the results have been conflicting.
Omega-3 fatty acid supplementation has been found to
reduce inflammatory biomarkers in populations with
various chronic inflammatory or non-inflammatory dis-
eases [10, 18, 19]. Importantly, the Vitamin D and
Omega-3 trial (VITAL) found no decrease in inflamma-
tory markers in subjects that used either 1 g omega-3 or
50 μg vitamin D daily for 1 year [20].
The anti-inflammatory properties of CLO are less ex-
plored. Our study showed that the anti-inflammatory ef-
fect was largest in CLO users. One earlier randomized
controlled trial found that supplementation with CLO
was associated with a decrease in CRP in a cohort of
women with gestational diabetes. The authors attributed
this to the content of omega-3 PUFAs in CLO [21]. The
possible impact of the other components of CLO, such
as vitamins A, E and D, were not discussed [21]. These
vitamins, present both in CLO and some other omega-3
fatty acid supplements, may contribute to anti-
inflammatory effects. Vitamin E is an antioxidant, which
theoretically could be beneficial in neutralizing the ef-
fects of oxygen free radicals, but prior studies have been
conflicting [22, 23]. PUFAs are important components
of cell membranes [24]. Oxygen free radicals react more
quickly with vitamin E than with PUFAs, hence the pres-
ence of vitamin E may protect the integrity of the cell
membranes, in turn preventing cell damage [25, 26].
Furthermore, the vitamin A precursor, beta-carotene,
and vitamin E have been associated with reduction in
muscle damage and enhanced recovery from exercise
[27]. Vitamin D is mostly considered to be important in
regulating calcium and phosphate metabolism, however,
some studies also report on anti-inflammatory effects of
vitamin D supplements [28, 29]. Whether the presence
of these vitamins and possible differences in vitamin
content between supplements may contribute to the at-
tenuation of the exercise-induced CRP response found
Fig. 3 Mean delta CRP increase from baseline to 24 h after the race
in subjects who use CLO regularly (green) versus the rest of the
cohort (blue), divided into tertiles based on a) race duration and b)
body mass index
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in the present analysis, should be explored in future
studies.
The impact of quality, quantity and content
The observed anti-inflammatory differences between users
of CLO and other omega-3 fatty acid supplements in the
present study may relate to the quality of the supplement,
in particular the degree of oxidation of the fatty acids [30,
31]. The Global Organization for EPA and DHA Omega-
3 s has recommended a maximal limit of total oxidation
value (TOTOX) of 26 [32]. Recent studies have suggested
that high-quality fish oil supplements may have more
favourable effects than similar doses of more oxidized
PUFAs [33, 34]. More than 39% of omega-3 fatty acid sup-
plements exceeds the limit of excess oxidation [34–36].
Moreover, in a Norwegian study of over-the-counter
omega-3 fatty acid supplements the median TOTOX
value in 54 available supplements was 29.0 (minimum-
maximum: 8.1–113.6) [37]. The main CLO manufacturer
in Norway (Möller’s, Oslo) reports a TOTOX value of 4.1
[38]. The degree of oxidation might therefore be of im-
portance when interpreting these results.
The quantity of PUFA intake might further explain
some of the difference in effect observed in the present
study. As outlined in Table 1, the recommended daily
dose of CLO (5ml) contains 1.2 g of PUFAs. For other
omega-3 fatty acid supplements, intake is commonly
recommended as 1–4 capsules per day, making the exact
dose consumed difficult to assess. Furthermore, the spe-
cific content of EPA and DHA is also not always avail-
able. Conversely, some of the omega-3 fatty acid
products might yield lower PUFA intake as compared to
that of CLO supplements, particularly since CLO is
often consumed in a tablespoon, which contains 2–3
times the recommended daily dose [16].
EPA and DHA are usually both present in omega-3
fatty acid supplements. Emerging evidence suggests that
the two fatty acids have different health benefits. In the
Reduction of Cardiovascular Events with Icasopent
Ethyl-Intervention Trial (REDUCE-IT), use of 4 g of
PUFAs (icosapent ethyl) was found to lower the risk of
ischemic events in subjects with hypertriglyceridemia.
This product consists of 100% EPA, and corresponds to
10 times more EPA than the contents in a recom-
mended daily dose of CLO [39]. DHA has also been
shown to lower triglyceride levels, but might also in-
crease levels of low-density lipoprotein (LDL), and high-
density lipoprotein (HDL) [40, 41]. Furthermore, in the
Comparing EPA to DHA study (ComparED), DHA and
EPA were compared head-to-head and against placebo
in healthy subjects with abdominal obesity and subclin-
ical systemic inflammation, and results indicate that
DHA at a dose of 3 g/day for 10 weeks may be more ef-
fective than a similar dose of EPA in attenuating
inflammation [40]. However, a meta-analysis by Li et al.
concluded that a higher daily dose of EPA lead to greater
lowering effect on CRP in healthy subjects, as compared
to DHA or omega-3 fatty acid supplements. DHA, on
the other hand, was found to have a dose-dependent de-
crease of the level of the pro-inflammatory cytokine IL-6
[42]. These underlying differences among supplements
used by the current study participants may explain some
of the observed differences in effect.
In the present analysis, the least fit subjects with the
highest BMI had the highest exercise-induced CRP
levels. This is in line with our previous study demon-
strating a strong correlation between fitness and post-
exercise CRP levels [2]. In the present study, regular use
of CLO was associated with lower CRP levels both at
baseline and following exercise compared with all other
groups. Importantly, the largest benefits of CLO use on
CRP levels, were found in the least fit subjects and in
subjects with the highest BMI levels (Fig. 3). Obesity is
characterized by a low-grade chronic inflammation [43].
In line with our findings at rest, prior studies have dem-
onstrated significant reductions in baseline inflammatory
markers such as IL-6 (up-stream of CRP) in obese sub-
jects receiving EPA and DHA [44, 45]. To our know-
ledge the present study is the first to suggest that there
may be an increased beneficial effect of CLO on
exercise-induced inflammation in moderately obese indi-
viduals with reduced fitness. The reason for the differ-
ence in CRP levels between CLO and other omega-3
supplements is not clear. The difference may relate to
amount, quality or balance of the different PUFAs and
other contents of CLO compared with the other supple-
ments as discussed above. The present findings suggest
that regular use of CLO may have a beneficial effect by
attenuating post-exercise inflammation, potentially redu-
cing the post-exercise discomfort, and thereby increasing
the motivation to increase exercise in overweight and
obese individuals with reduced fitness.
Limitations
There are several limitations to the present study. The
main limitations relate to the observational study design,
and the lack of information on supplement manufacturer,
content, duration and quantity of supplement used. In
previous studies, intake of CLO has been reported to be
significantly lower in people with lower socioeconomic
rank and education [16]. In our material, however, 63.6%
of non- and sporadic users of omega-3 fatty acid subjects
reported higher education, vs 60.6% among regular users
of omega-3 fatty acid supplements, p = 0.24.
Conclusion
In this large-scale study on healthy recreational athletes,
the exercise-induced CRP was attenuated in subjects
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who used omega-3 fatty acid supplement regularly. This
effect was driven by the users of CLO supplements.
These findings imply that regular use of CLO supple-
ments may be associated with a reduction in both basal
and exercise-induced inflammation in athletes. The asso-
ciation between lower exercise-induced inflammation,
PUFA intake, and potential effects on recovery parame-
ters needs to be further elucidated in future studies.
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